연부조직 육종 시장 규모, 점유율 및 성장 분석 : 유형별, 진단별, 치료법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Soft Tissue Sarcoma Market size was valued at USD 4.11 Billion in 2024 and is poised to grow from USD 4.45 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for soft tissue sarcoma is experiencing rapid growth driven by the rising incidence of cancer, heightened awareness of rare oncological conditions, and a robust pipeline of innovative therapies. Advancements in diagnostic technologies, including MRI and PET scans, facilitate early detection, leading to improved treatment options. Increased investment from major pharmaceutical companies in targeted therapies, such as tyrosine kinase inhibitors and immunotherapies, further propels market expansion. Regulatory support for faster drug approvals and orphan designations has encouraged the development of novel treatments. However, challenges persist, including a limited patient population, high treatment costs, and complexities in early diagnosis. Additionally, the heterogeneous nature of soft tissue sarcomas complicates clinical trials, while side effects from standard treatments may hinder adherence, especially in developing regions lacking specialized healthcare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Soft Tissue Sarcoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Soft Tissue Sarcoma Market Segments Analysis

Global Soft Tissue Sarcoma Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. Based on Diagnosis, the market is segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI) and Others. Based on Treatment, the market is segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy and Surgery. Based on End User, the market is segmented into Hospitals and Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is primarily driven by the rising incidence and prevalence of various forms of soft tissue sarcoma worldwide. Enhanced diagnostic techniques and a deeper understanding of the disease have contributed to the identification of more cases, consequently increasing the demand for effective treatment options. This growing need encompasses a range of therapeutic approaches, including surgical procedures, radiation therapy, chemotherapy, and innovative targeted therapies. As awareness and detection continue to improve, the market is poised for expansion, reflecting the urgency for advanced treatment solutions that cater to the diverse needs of patients diagnosed with soft tissue sarcoma.

Restraints in the Global Soft Tissue Sarcoma Market

One of the significant obstacles facing the global soft tissue sarcoma market is the uncommon nature and considerable heterogeneity of the disease. Soft tissue sarcoma comprises various histological subtypes, each displaying distinct biological behaviors and varying responses to treatment. This rarity presents challenges in organizing large-scale clinical trials and ultimately hinders the development of effective therapies. Furthermore, the diversity among subtypes complicates the standardization of treatment approaches, resulting in a fragmented understanding of the disease. This situation complicates research efforts and slows down advancements in innovative solutions for patients affected by soft tissue sarcoma.

Market Trends of the Global Soft Tissue Sarcoma Market

The Global Soft Tissue Sarcoma market is witnessing a significant shift towards the emergence and adoption of targeted therapies and immunotherapies, reflecting a broader trend in oncology. These innovative treatment modalities are transforming patient outcomes by specifically targeting cancer cells and leveraging the immune system, offering enhanced efficacy with potentially reduced toxicity compared to conventional chemotherapy. As healthcare providers and researchers focus on personalized medicine, the demand for these advanced therapies is increasing, driving investments in research and development. This shift not only fosters improved treatment options but also encourages a more patient-centric approach in the management of soft tissue sarcoma.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Soft Tissue Sarcoma Market Size by Type & CAGR (2026-2033)

• Market Overview
• Angiosarcoma
• Epithelioid Sarcoma
• Gastrointestinal Stromal Tumor (GIST)
• Others

Global Soft Tissue Sarcoma Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Biopsy
• Ultrasound Scan
• Magnetic Resonance Imaging (MRI)
• Others

Global Soft Tissue Sarcoma Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Surgery

Global Soft Tissue Sarcoma Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers
• Others

Global Soft Tissue Sarcoma Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, End User)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunomedics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epizyme, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations